ADVERTISEMENT
PSMA-Targeting Therapy Shows Promise, Precision in Patients With mCRPC
177Lu-PSMA-617 was reported as a promising targeted anti-tumor growth radioligand therapy with primary end points met for overall survival (OS) and radiographic progression-free survival (PFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to data from the phase 3 VISION trial.
Investigators sought to assess the efficacy, safety, and clinical benefit of 177Lu-PSMA-617 with patients randomized to receive 7.4 GBq intravenously every 6 weeks for a maximum of 6 cycles. Additionally, 177Lu-PSMA-617 expressed potentiality through phenotypic precision medicine.
“Radioligand therapy combines a targeting compound that binds to markers expressed by tumors and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. This therapeutic approach enables targeted delivery of radiation to the tumor, while limiting damage to the surrounding normal tissue,” wrote Dr Oliver Sartor, MD, the School of Medicine, Tulane University, New Orleans, and co-investigators.
831 patients were enrolled and randomly assigned to the 177Lu-PSMA-617 plus investigator-chosen best standard of care (BSC) investigational arm or the BSC control arm. Patients with PSMA PET-scan positive mCRPC and progression after prior taxane and androgen receptor-directed therapy (ARDT) were randomized in a 2:1 ratio in favor of the investigational arm.
The primary objective of the study was to compare the primary endpoints of OS and PFS.
Findings show that the median OS was 13.7 months with a hazard ratio (HR) of 0.73 and PFS of 6 months with an HR of 0.67, respectively.
“The trial met both primary end points of OS and radiographic PFS, helping to move closer the ambition of becoming the targeted treatment for >80% of patients with advanced prostate cancer,” concluded Dr Sartor et al. – Alexa Stoia
